ArticleNucleic acids research2026
Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposing.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The ROBOKOP v1.0 knowledge graph system for exploring relationships between biomedical entities.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Drug databases typically aim to provide reference information on medications and their uses but often lack strict definitions of the terms drug (e.g. approved or a clinical candidate) or disease, and do not focus on any specific context of use. The recent emergence of biomedical knowledge graphs, which integrate diverse biomedical data into a contiguous, harmonized knowledge network, has enabled innovation in drug repurposing (identification of novel uses of existing drugs). This objective has created a new set of requirements and challenges for drug databases to be used for generating high-confidence, testable drug repurposing hypotheses. To address this challenge, we have developed MeDIC as an open, foundational database built from government regulatory sources only, which comprises highly curated lists of drugs (including combination therapies), diseases, indications (i.e. drug approvals to treat specific diseases), contraindications, and additional metadata. MeDIC allows for easy maintainability, open-source adaptability, and ongoing updates concordant with updates of primary sources. To facilitate downstream use, MeDIC is provided in a tabulated format, and each drug, disease, indication, or contraindication entry is mapped to multiple ontologies. We offer MeDIC as a web-based, freely accessible (https://medic.renci.org), downloadable (including lists and source code), searchable, and machine learning-friendly resource for patients, providers, and researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.